Merck/Bayer’s Vericiguat Outcomes Data Less Impressive On Fuller Disclosure

Efficacy seen in reducing hospitalization in high-risk heart failure patients, but not in reducing the risk of cardiovascular death. Analysts say this portends a more niche opportunity for vericiguat.